{"organizations": [], "uuid": "4199589273b2d5772075d2ef688a5d1e293b43ce", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-abbvie-announces-positive-results/brief-abbvie-announces-positive-results-from-second-phase-3-study-of-elagolix-in-women-with-uterine-fibroids-idUSFWN1QV0N4", "country": "US", "domain_rank": 408, "title": "BRIEF-Abbvie Announces Positive Results From Second Phase 3 Study Of Elagolix In Women With Uterine Fibroids", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-13T14:26:00.000+02:00", "replies_count": 0, "uuid": "4199589273b2d5772075d2ef688a5d1e293b43ce"}, "author": "", "url": "https://www.reuters.com/article/brief-abbvie-announces-positive-results/brief-abbvie-announces-positive-results-from-second-phase-3-study-of-elagolix-in-women-with-uterine-fibroids-idUSFWN1QV0N4", "ord_in_thread": 0, "title": "BRIEF-Abbvie Announces Positive Results From Second Phase 3 Study Of Elagolix In Women With Uterine Fibroids", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "elagolix in women with uterine fibroids reuters", "sentiment": "none"}, {"name": "abbvie inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 13, 2018 / 12:27 PM / in 13 minutes BRIEF-Abbvie Announces Positive Results From Second Phase 3 Study Of Elagolix In Women With Uterine Fibroids Reuters Staff 1 Min Read March 13 (Reuters) - Abbvie Inc: * ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM SECOND PHASE 3 STUDY EVALUATING INVESTIGATIONAL ELAGOLIX IN WOMEN WITH UTERINE FIBROIDS * ABBVIE INC - ‍SECOND OF TWO PIVOTAL PHASE 3 STUDIES (ELARIS UF-II) MET PRIMARY EFFICACY ENDPOINT AND ALL RANKED SECONDARY ENDPOINTS​ * ABBVIE INC - ‍RESULTS WERE CONSISTENT WITH FIRST PHASE 3 STUDY​ * ABBVIE INC - STUDY ALSO MET ALL RANKED SECONDARY ENDPOINTS (P<0.02) AT MONTH SIX * ABBVIE INC - ‍RESULTS DEMONSTRATED ELAGOLIX, WITH LOW-DOSE ADD-BACK THERAPY, REDUCED HEAVY MENSTRUAL BLEEDING COMPARED TO PLACEBO​ * ABBVIE INC - ‍WOMEN IN STUDY WILL CONTINUE IN EITHER POST-TREATMENT FOLLOW-UP OR A BLINDED SIX-MONTH EXTENSION STUDY​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-13T14:26:00.000+02:00", "crawled": "2018-03-13T14:42:54.009+02:00", "highlightTitle": ""}